| Title： | Chinese Experts Consensus on Diagnosis and Clinical Application of HER2 in Biliary Tract Malignancies |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | doctors, clinical experts |
| Evidence classification method： | The Grading of evidence-based medicine evidence in this consensus is based on the Grading of recommendations, assessment, development and evaluation（GRADE) and Oxford Center for Evidence-Based Medicine Grading 2011 edition, the strength of expert recommendation mainly refers to the GRADE guiding principles for grading recommendations, and the grading of recommendations is partially modified in combination with the grading scheme of ASCO guidelines. In this paper, recommendations are divided into three grades: A (strong recommendation), B (moderate recommendation) and C (weak recommendation) |
| Development unit： | Eastern Hepatobiliary Surgery Hospital, Navy Medical University |
| Registration time: | 2024-09-09 |
| Registration number： | PREPARE-2024CN449 |
| Purpose of the guideline: | Biliary tract cancers (BTC) are a class of tumors with high malignancy and poor prognosis. With the deepening understanding of the genomic and proteomic characteristics of BTC, precision targeted therapy has made rapid progress. In recent years, multiple clinical studies targeting human epidermal growth factor receptor 2 (HER2) have achieved positive results. However, there are still urgent clinical and scientific issues to be addressed regarding the BTC HER2 assessment and anti-HER2 treatment. To better guide the molecular diagnosis and clinical application of BTC HER2, the "Chinese Experts Consensus on Molecular Diagnosis and Clinical Application of HER2 in Biliary Tract Malignancies (2024 Edition)" has been formulated based on existing medical evidence and clinical practice experience, providing a reference for domestic peers. |
